AstraZeneca reprimanded for nolvadex advertisement.
Fintor
Lou
L
D000329:Advertising / Q000592:standards*; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects; D004345:Drug Industry / Q000592:standards*; D006801:Humans; D020845:Selective Estrogen Receptor Modulators / Q000009:adverse effects; D013629:Tamoxifen / Q000009:adverse effects; D014481:United States; D014486:United States Food and Drug Administration
D018931:Antineoplastic Agents, Hormonal; D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen